Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

103 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

NCT00594646

HIV Infections

COMPLETED PHASE4

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

NCT02131233

HIV Infection

COMPLETED PHASE3

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

NCT00745823

HIV

TERMINATED PHASE3

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

NCT00293254

HIV Infections

COMPLETED PHASE3

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

NCT00293267

HIV Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-Occupational Post-Exposure Prophylaxis (nPEP) after sexual exposure to HIV is recommended by the Centers for Disease Control (CDC). Although no efficacy data exist for Post-Exposure Prophylaxis (PEP) after sexual exposure, PEP has been shown to reduce HIV transmission in other exposure situations such as occupational exposures and mother-to-child transmission. The role in nPEP of the newer agents approved for the treatment of HIV infection remains unknown. The anti-HIV drug raltegravir works early in the life cycle of the virus, before it integrates with human DNA. It has few side effects and drug interactions what makes it an ideal drug for an nPEP regimen.

We aim to asses the safety and tolerability of the combination of truvada and raltegravir for nPEP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Truvada and Raltegravir

Single arm

Group Type OTHER

Truvada

Intervention Type DRUG

Tenofovir 200mg/emtricitabine 300mg once a day

Raltegravir

Intervention Type DRUG

Raltegravir 400mg twice a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Truvada

Tenofovir 200mg/emtricitabine 300mg once a day

Intervention Type DRUG

Raltegravir

Raltegravir 400mg twice a day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tenofovir 200mg/emtricitabine 300mg Isentress

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must be at least 18 years of age
* HIV uninfected on the basis of a negative HIV rapid test, EIA or Western blot, and without any signs or symptoms of acute HIV infection
* Able to understand and provide consent
* High-Risk Exposure Characteristic (One or more of the below, unprotected or with failed condom use):

* Receptive Anal Intercourse
* Insertive Anal Intercourse
* Receptive Vaginal Intercourse
* Insertive Vaginal Intercourse
* Receptive Oral Intercourse with Intraoral Ejaculation with known HIV+ source
* High-Risk Source (One or more of the below):

* Known HIV positive
* MSM
* MSM/W
* CSW
* Sexual perpetrator Partner of one of the above
* Exposure within 72 hours of presentation
* Not known to be HIV-1 positive
* No countermanding concomitant medications or allergies

Exclusion Criteria

* Patients \<18 years of age
* Unable to understand and provide consent
* Non-occupational exposure to HIV-1 not recent enough to commence the first dose of study medication within 72 hours from the exposure
* Known to be HIV positive
* Any condition which in the opinion of the intake provider will seriously compromise the patient's ability to comply with the protocol, including adherence to nPEP medication
* Demonstrated HIV-1 positive on rapid testing
* Unwillingness to commit to barrier-method (male and/or female condom) use until HIV negative status is confirmed 6 months after exposure
* Unwillingness of breast-feeding women to transition to formula feeding
* Any active psychiatric illness or active drug or alcohol abuse that, in the opinion of the investigator, could prevent compliance with study procedures
* Pregnancy
* Chronic hepatitis B infection, diagnosed by either positive serum HBsAg or positive serum HBV DNA; or prior lamivudine or other therapy for hepatitis B
* Creatinine clearance less than 30 mL/min as calculated by Cockcroft-Gault formula
* Unwillingness to participate in study procedures, including Mental Health referral and intervention
* Known intolerance or allergy to tenofovir DF, emtricitabine or raltegravir
* Use of prohibited concomitant medication: dilantin, phenobarbital and rifampin which cannot be used with raltegravir

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No